Nov. 26, 2007
UI study seeks people ages 18 to 80 with atrial fibrillation
People ages 18 to 80 who have atrial fibrillation (an abnormal heart rhythm) may be eligible to participate in a research study of an anti-clotting medication for reducing the risk of blood clots that can lead to stroke.
The study will compare an experimental anti-clotting medication with the currently used medication, warfarin, to determine if it is as effective as warfarin in reducing the formation of blood clots in the hearts of patients with atrial fibrillation.
Study participants will be randomly assigned to receive either warfarin or one of four different doses of the investigational medication.
Participation in the study involves an initial screening visit at UI Hospitals and Clinics to determine eligibility. The study will last approximately five months and will include 11 clinic visits. At these visits blood and urine samples will be tested to monitor blood-clotting and kidney and liver function. Participants also will get an electrocardiogram (ECG) at the beginning and end of the study.
Qualifying participants will receive laboratory evaluations, physical exams and electrocardiograms and study medications at no cost. Compensation also will be provided for travel and parking.
The study aims to recruit about 2,000 subjects worldwide including at the UI, where the principal investigator is Jennifer Robinson, M.D., M.P.H., associate professor of epidemiology in the UI College of Public Health and director of the UI Lipid Research Center.
For more information, call the UI Lipid Research Clinic toll free at 800-887-6917 or 319-384-5046.
STORY SOURCE: Health Science Relations, University of Iowa, 5137 Westlawn Lawn, Iowa City, IA 52242
MEDIA CONTACT: Becky Soglin, Health Science Relations, 319-335-6660, email@example.com; Writer: Jennifer Brown